Body fat changes and lipodystrophy in HIV-infected children: Impact of highly active antiretroviral therapy [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 1, 2006, Pages 121-123

  Dzwonek, Agnieszka B ^a   Lawson, Margaret S ^a   Cole, Tim J ^a   Novelli, Vas ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADIPOSE TISSUE; ANTHROPOMETRY; BLOOD SAMPLING; BODY COMPOSITION; BODY FAT; BODY FAT DISTRIBUTION; BODY MASS; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIPODYSTROPHY; LONG TERM CARE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANK SUM TEST; STATISTICAL ANALYSIS; UNITED KINGDOM;

ADIPOSE TISSUE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; REPRODUCIBILITY OF RESULTS;

EID: 33748114493     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000230523.94588.85     Document Type: Letter

References (13)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Carr A, Samaras K, Chisholm DJ, et al. Abnormal fat distribution and use of protease inhibitors. Lancet. 1998;351:1736.
3. Mallon PW, Cooper DA, Carr A. HIV-associated lipodystrophy. HIV Med. 2001;2:166-173.
4. Nolan D, Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther. 2004;9:849-863.
5. van der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847-855.
6. Amaya RA, Kozinetz CA, McMeans A, et al. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:405-410.
7. European Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004;18:1443-1451.
8. Freeman JV, Cole TJ, Chinn S, et al. Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child. 1995;73:17-24.
9. Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child. 1995;73:25-29.
10. Gerver WJ, Bruin R. Paediatric Morphometrics. A Reference Manual, 2nd ed. Maastricht, The Netherlands: Universitaire Pers Maastricht; 2001.
11. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4:293-301.
12. Vigano A, Mora S, Brambilla P, et al. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents. AIDS. 2003;17:1435-1441.
13. He Q, Horlick M, Thornton J, et al. Sex and race differences in fat distribution among Asian, African-American, and Caucasian prepubertal children. J Clin Endocrinol Metab. 2002;87:2164-2170.